First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.

被引：0
|
作者：
Camidge, D. Ross
Bazhenova, Lyudmila
Salgia, Ravi
Weiss, Glen J.
Langer, Corey J.
Shaw, Alice Tsang
Narasimhan, Narayana I.
Dorer, David J.
Rivera, Victor M.
Zhang, Joshua
Clackson, Tim
Haluska, Frank G.
Gettinger, Scott N.
机构：
[1] Univ Colorado, Ctr Canc, Aurora, CO USA
[2] UC San Diego Moores Canc Ctr, La Jolla, CA USA
[3] Univ Chicago, Chicago, IL 60637 USA
[4] Virginia G Piper Canc Ctr, Scottsdale Healthcare Program, Scottsdale, AZ USA
[5] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[6] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[7] ARIAD Pharmaceut Inc, Cambridge, MA USA
[8] Yale Univ, Sch Med, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8031
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Updated results from a phase I, open-label, multicenter, first-in-human study of AMG 404, a checkpoint inhibitor, in patients with advanced solid tumors
    Price, T. J.
    Prenen, H.
    Lugowska, I.
    Falchook, G. S.
    Monzon, J. G.
    Arkenau, H. T.
    Chawla, S. P.
    Hui, M. N.
    Kuboki, Y.
    Dziadziuszko, R.
    Ozawa, Y.
    Fernandez, M. E. Elez
    Lima, C. S. P. Rocha
    Subbiah, V.
    Tan, D. S. W.
    Wang, K.
    Hindoyan, A.
    Shi, W.
    Kistler, M.
    Sadraei, N. Hashemi
    ANNALS OF ONCOLOGY, 2021, 32 : S1440 - S1442
  • [32] PHASE 1/2 STUDY OF AP26113 IN PATIENTS (PTS) WITH ADVANCED MALIGNANCIES, INCLUDING ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF SAFETY AND EFFICACY AT SELECTED PHASE 2 DOSES
    Rosell, R.
    Gettinger, S.
    Bazhenova, L. A.
    Langer, C. J.
    Salgia, R.
    Gold, K.
    Shaw, A. T.
    Dorer, D. J.
    Kerstein, D.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2015, 26
  • [33] Phase I dose-finding study of the SIRPa inhibitor BI 765063 as monotherapy in Japanese patients with advanced cancer
    Doi, Toshihiko
    Aogi, Kenjiro
    Tamiya, Motohiro
    Block, Eric
    Tachibana, Yoshifumi
    Sarashina, Akiko
    Yamamoto, Noboru
    ANNALS OF ONCOLOGY, 2023, 34 : S1403 - S1403
  • [34] SAF-189s in previously treated patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC): Results from the dose-finding portion in a single-arm, first-in-human phase I/II study.
    Yang, Jin-Ji
    Zhou, Jianying
    Yang, Nong
    Wu, Zhuli
    Sun, Juan
    Hui, Ai-Min
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
    Ou, Sai-Hong Ignatius
    Janne, Pasi A.
    Leal, Ticiana A.
    Rybkin, Igor I.
    Sabari, Joshua K.
    Barve, Minal A.
    Bazhenova, Lyudmila
    Johnson, Melissa L.
    Velastegui, Karen L.
    Cilliers, Cornelius
    Christensen, James G.
    Yan, Xiaohong
    Chao, Richard C.
    Papadopoulos, Kyriakos P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (23) : 2530 - +
  • [36] A first-in-human dose escalation and dose-finding phase I/II trial of IMAB027 in patients with recurrent advanced ovarian cancer (GM-IMAB-002-01)
    Jaeger, Dirk
    Sahin, Ugur
    Tureci, Oezlem
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies
    Lakhani, Nehal J.
    Papadopoulos, Kyriakos P.
    Johnson, Melissa Lynne
    Park, Haeseong
    Wang, Ding
    Yap, Timothy A.
    Dowlati, Afshin
    Maki, Robert G.
    Ulahannan, Susanna
    Lynce, Filipa
    Kelly, Karen
    Williamson, Stephen
    Malhotra, Jyoti
    Chen, Shuquan
    Gonzalez Ortiz, Ana
    Jankovic, Vladimir
    Paccaly, Anne
    Masinde, Sheila
    Mani, Jayakumar
    Lowy, Israel
    Gullo, Giuseppe
    Sims, Tasha
    Kroog, Glenn
    CLINICAL CANCER RESEARCH, 2024, 30 (24) : 5601 - 5611
  • [38] First-in-human study of TQB3617, a BET inhibitor in patients with relapsed/refractory hematologic malignancies
    Cai, Qingqing
    Xia, Yi
    Yin, Qingsong
    Wang, Liang
    Zhao, Baitian
    Cai, Jun
    Fang, Xiaojie
    Ding, Dawei
    Zhang, Bo
    Yu, Ding
    Wang, Xunqiang
    Zhang, Xiquan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] A first-in-human phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLC.
    Kiura, Katsuyuki
    Seto, Takashi
    Yamamoto, Nobuyuki
    Nishio, Makoto
    Nakagawa, Kazuhiko
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.
    Juergens, Rosalyn A.
    Chu, Quincy S.
    Renouf, Daniel John
    Laurie, Scott Andrew
    Purcea, Daniela
    McWhirter, Elaine
    Arndt, Diane
    Gelmon, Karen A.
    Hilton, John
    Gavillet, Bruno
    Ellis, Peter Michael
    Sawyer, Michael B.
    Kollmannsberger, Christian K.
    Wright, Natalie Andrews
    Rouits, Elisabeth
    Brichory, Frank
    Vuagniaux, Gregoire
    Szyldergemajn, Sergio A.
    Goss, Glenwood
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345